# EDGAR Filing Document

**Accession Number:** 0000896262
**File Stem:** 0000896262-25-000061
**Filing Date:** 2025-7
**Character Count:** 51958
**Document Hash:** eb47446725362a640a84990d22c74981
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000896262-25-000061.hdr.sgml**: 20250729

**ACCESSION NUMBER**: 0000896262-25-000061

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 27

**CONFORMED PERIOD OF REPORT**: 20250729

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250729

**DATE AS OF CHANGE**: 20250729

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMEDISYS INC
- **CENTRAL INDEX KEY:** 0000896262
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HOME HEALTH CARE SERVICES [8082]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 113131700
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-24260
- **FILM NUMBER:** 251162638

**BUSINESS ADDRESS:**
- **STREET 1:** 3854 AMERICAN WAY
- **STREET 2:** SUITE A
- **CITY:** BATON ROUGE
- **STATE:** LA
- **ZIP:** 70816
- **BUSINESS PHONE:** 2252922031

**MAIL ADDRESS:**
- **STREET 1:** 3854 AMERICAN WAY
- **STREET 2:** SUITE A
- **CITY:** BATON ROUGE
- **STATE:** LA
- **ZIP:** 70816

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANALYTICAL NURSING MANAGEMENT CORP
- **DATE OF NAME CHANGE:** 19940819

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** M&N CAPITAL CORP
- **DATE OF NAME CHANGE:** 19930125

?xml version='1.0' encoding='ASCII'? amed-20250729

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

**DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 29, 2025** 

**Commission File Number: 0-24260**![image0.jpg](amed-20250729_g1.jpg)

**AMEDISYS, INC.**

**(Exact Name of Registrant as specified in its Charter)** 

---

| | |
|:---|:---|
| **Delaware** | **11-3131700** |
| **(State or other jurisdiction of** <br>**incorporation or organization)** | **(I.R.S. Employer** <br>**Identification No.)** |

---

**3854 American Way, Suite A, Baton Rouge, LA 70816** 

**(Address of principal executive offices, including zip code)**

**(225) 292-2031 or (800) 467-2662**

**(Registrant's telephone number, including area code)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, par value $0.001 per share** | **AMED** | **The NASDAQ Global Select Market** |

---

---

| | |
|:---|:---|
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
| Emerging growth company  | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻  | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻  |

---

------

**SECTION 2 — FINANCIAL INFORMATION**

**ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION**

On July 29, 2025, the Company issued a press release (the "Press Release") announcing its financial results for the three and six-month periods ended June 30, 2025. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information presented in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless we specifically state that the information is to be considered "filed" under the Exchange Act or specifically incorporate it by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act.

**SECTION 7 — REGULATION FD**

**ITEM 7.01. REGULATION FD DISCLOSURE**

Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference.

In addition, a copy of the Company's second quarter supplemental slides are attached to this report as Exhibit 99.2 and incorporated herein by reference.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibits 99.1 and 99.2 hereto) is being "furnished" and shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibits 99.1 and 99.2 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

------

**SECTION 9 — FINANCIAL STATEMENTS AND EXHIBITS**

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

---

| | |
|:---|:---|
| 99.1 | <u>[Press release dated](a20253006_991exhibit.htm)[July 29](a20253006_991exhibit.htm)[, 2025 announcing the Company's results for the three](a20253006_991exhibit.htm)[and six](a20253006_991exhibit.htm)[-month period](a20253006_991exhibit.htm)[s](a20253006_991exhibit.htm)[ended](a20253006_991exhibit.htm)[June 30](a20253006_991exhibit.htm)[, 2025 (furnished only)](a20253006_991exhibit.htm)</u> |
| 99.2 | <u>[Supplemental slides provided in connection with the](amed2q25ecsupplementalsl.htm)[second](amed2q25ecsupplementalsl.htm)[quarter 2025 earnings release (furnished only)](amed2q25ecsupplementalsl.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMEDISYS, INC.

(Registrant)

By:&nbsp;&nbsp;&nbsp;&nbsp;<u>/s/ Scott G. Ginn</u> 

&nbsp;&nbsp;&nbsp;&nbsp;Scott G. Ginn

&nbsp;&nbsp;&nbsp;&nbsp;Chief Operating Officer, Executive Vice President and Chief Financial Officer

&nbsp;&nbsp;&nbsp;&nbsp;(Principal Financial Officer)

DATE: July 29, 2025

## Exhibit 99.1

 **Exhibit 99.1**

![draftof8k050418image1a.gif](draftof8k050418image1a.gif)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**AMEDISYS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS** 

BATON ROUGE, Louisiana (July 29, 2025) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2025.

<u>Three-Month Periods Ended June 30, 2025 and 2024</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net service revenue increased $30.7 million to $621.9 million compared to $591.2 million in 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net income attributable to Amedisys, Inc. of $28.1 million, which is inclusive of merger-related expenses totaling $26.3 million ($26.1 million, net of tax), compared to net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ($11.5 million, net of tax) in 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net income attributable to Amedisys, Inc. per diluted share of $0.84 compared to $0.98 in 2024.

<u>Adjusted Quarterly Results\*</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of $80.8 million compared to $73.2 million in 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net income attributable to Amedisys, Inc. of $51.4 million compared to $43.5 million in 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net income attributable to Amedisys, Inc. per diluted share of $1.54 compared to $1.32 in 2024.

<u>Six-Month Periods Ended June 30, 2025 and 2024</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net service revenue increased $54.0 million to $1,216.6 million compared to $1,162.6 million in 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net income attributable to Amedisys, Inc. of $89.1 million, which is inclusive of merger-related expenses totaling $43.0 million ($42.7 million, net of tax) and a $48.1 million gain on an equity method investment ($35.6 million, net of tax), compared to net income attributable to Amedisys, Inc. of $46.7 million, which is inclusive of merger-related expenses totaling $32.6 million ($31.3 million, net of tax) in 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net income attributable to Amedisys, Inc. per diluted share of $2.68 compared to $1.42 in 2024.

<u>Adjusted Year to Date Results\*</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of $149.6 million compared to $133.0 million in 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net income attributable to Amedisys, Inc. of $93.0 million compared to $77.5 million in 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net income attributable to Amedisys, Inc. per diluted share of $2.80 compared to $2.35 in 2024.

\* See pages 2 and 8 - 9 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.

The supplemental slides provided in connection with the second quarter 2025 earnings release can be found on the Investor Relations page of our website. In light of the pending merger of the Company with UnitedHealth Group Incorporated, Amedisys will not conduct a quarterly earnings call to discuss the second quarter results.

------

**Non-GAAP Financial Measures**

This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. ("GAAP") to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items; (2) adjusted net income attributable to Amedisys, Inc., defined as net income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items; and (3) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income attributable to Amedisys, Inc. common stockholders per diluted share calculated in accordance with GAAP excluding certain items. Certain items include merger-related expenses, impairment charges, unusual or non-recurring expenses and certain non-operational items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to, the GAAP financial measures presented in this earnings release and the company's financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.

**Additional Information**

Amedisys, Inc. (the "Company") is a leading healthcare services company, delivering personalized home health, hospice and high acuity care services in the home. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based recovery and rehabilitation after an operation or injury, care focused on empowering our patients to manage a chronic disease, hospice care at the end of life or in-patient hospital, palliative and skilled nursing facility ("SNF") care in their homes. More than 3,300 hospitals and 114,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 19,000 employees in 519 care centers within 38 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 499,000 patients every year. For more information about the Company, please visit: www.amedisys.com.

We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled "Investors" on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.

------

**Forward-Looking Statements**

When included in this press release, words like "believes," "belief," "expects," "strategy," "plans," "anticipates," "intends," "projects," "estimates," "may," "might," "will," "could," "would," "should" and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to, the following: disruption from the proposed merger with UnitedHealth Group with patient, payor, provider, referral source, supplier or management and employee relationships; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement with UnitedHealth Group or the inability to complete the proposed transaction on the anticipated terms or by the end of the waiver period under the merger agreement; the risk that necessary regulatory approvals for the proposed merger with UnitedHealth Group are delayed, are not obtained or are obtained subject to conditions that are not anticipated; the failure of the conditions to the proposed merger to be satisfied; the costs related to the proposed transaction; the diversion of management time on merger-related issues; the risk that termination fees may be payable by the Company in the event that the merger agreement is terminated under certain circumstances; reputational risk related to the proposed merger; the risk of litigation or regulatory action related to the proposed merger, including among other things, the action by the Department of Justice to block the merger; changes in Medicare and other medical payment levels; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients and payment methodologies; staffing shortages driven by the competitive labor market; our ability to attract and retain qualified personnel; competition in the healthcare industry; our ability to maintain or establish new patient referral sources; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; changes in estimates and judgments associated with critical accounting policies; our ability to consistently provide high-quality care; our ability to keep our patients and employees safe; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural or man-made disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; our ability to integrate, manage and keep our information systems secure; the impact of inflation; the impact of new or increased tariffs; uncertainty around, and disruption from, new and emerging technologies, including the adoption and utilization of artificial intelligence ("AI") and generative AI and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking, and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

**Contact:&nbsp;&nbsp;&nbsp;&nbsp;<u>Investor Contact:</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Media Contact:</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

**Amedisys, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amedisys, Inc.**

**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nick Muscato&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kendra Kimmons**

**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Strategy Officer &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vice President, Marketing & Communications**

**&nbsp;&nbsp;&nbsp;&nbsp;(615) 928- 5452&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(225) 299-3720**

**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**<u>IR@amedisys.com</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>kendra.kimmons@amedisys.com</u>

&nbsp;&nbsp;&nbsp;&nbsp;

------

**AMEDISYS, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED INCOME STATEMENTS**

**(Amounts in thousands, except per share data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three-Month <br>Periods Ended June 30,** | **For the Three-Month <br>Periods Ended June 30,** | **For the Six-Month<br>Periods Ended June 30,** | **For the Six-Month<br>Periods Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net service revenue | $621861 | $591187 | $1216642 | $1162601 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of service, inclusive of depreciation | 348470 | 326933 | 682520 | 648470 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Salaries and benefits | 130322 | 129323 | 262290 | 257269 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash compensation | 7266 | 7828 | 13489 | 15261 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Merger-related expenses | 26277 | 11901 | 43046 | 32568 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 4372 | 4386 | 8819 | 8657 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment | 883 |  | 883 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 58693 | 58602 | 116658 | 116543 |
| Total operating expenses | 576283 | 538973 | 1127705 | 1078768 |
| Operating income | 45578 | 52214 | 88937 | 83833 |
| Other income (expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income | 3016 | 1617 | 5889 | 3344 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (6415) | (7895) | (12837) | (16014) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity in earnings from equity method investments | 1641 | 1515 | 3435 | 2425 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on equity method investment |  |  | 48093 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Miscellaneous, net | 4506 | 1779 | 6014 | 2869 |
| Total other income (expense), net | 2748 | (2984) | 50594 | (7376) |
| Income before income taxes | 48326 | 49230 | 139531 | 76457 |
| Income tax expense | (19274) | (16657) | (48658) | (29290) |
| Net income | 29052 | 32573 | 90873 | 47167 |
| Net income attributable to noncontrolling interests | (968) | (272) | (1777) | (466) |
| Net income attributable to Amedisys, Inc. | $28084 | $32301 | $89096 | $46701 |
| Basic earnings per common share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to Amedisys, Inc. common stockholders | $0.85 | $0.99 | $2.71 | $1.43 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weighted average shares outstanding | 32849 | 32706 | 32822 | 32688 |
| Diluted earnings per common share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to Amedisys, Inc. common stockholders | $0.84 | $0.98 | $2.68 | $1.42 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weighted average shares outstanding | 33289 | 33047 | 33231 | 32992 |

---

------

**AMEDISYS, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(Amounts in thousands, except share data)**

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| **ASSETS** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $337304 | $303242 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patient accounts receivable | 295521 | 296075 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 18282 | 13072 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 11091 | 19694 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 662198 | 632083 |
| Property and equipment, net of accumulated depreciation of $104,613 and $100,890 | 38273 | 42108 |
| Operating lease right of use assets | 86614 | 81500 |
| Goodwill | 1213888 | 1213888 |
| Intangible assets, net of accumulated amortization of $21,134 and $18,787 | 79243 | 81155 |
| Other assets | 135169 | 87980 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $2215385 | $2138714 |
| **LIABILITIES AND EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $29789 | $39956 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payroll and employee benefits | 138515 | 151995 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 150379 | 152564 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination fee paid by UnitedHealth Group | 106000 | 106000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term obligations | 36799 | 37968 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of operating lease liabilities | 26879 | 25909 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 488361 | 514392 |
| Long-term obligations, less current portion | 326425 | 339313 |
| Operating lease liabilities, less current portion | 60404 | 56111 |
| Deferred income tax liabilities | 64445 | 48051 |
| Other long-term obligations | 847 | 882 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 940482 | 958749 |
| Equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.001 par value, 60,000,000 shares authorized; 38,476,503 and 38,307,521 shares issued; 32,881,262 and 32,776,148 shares outstanding | 38 | 38 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 833099 | 818201 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treasury stock, at cost, 5,595,241 and 5,531,373 shares of common stock | (480859) | (474854) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 880252 | 791156 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Amedisys, Inc. stockholders' equity | 1232530 | 1134541 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Noncontrolling interests | 42373 | 45424 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 1274903 | 1179965 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and equity | $2215385 | $2138714 |

---

------

**AMEDISYS, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING**

**(Amounts in thousands, except statistical information)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three-Month <br>Periods Ended June 30,** | **For the Three-Month <br>Periods Ended June 30,** | **For the Six-Month <br>Periods Ended June 30,** | **For the Six-Month <br>Periods Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Cash Flows from Operating Activities:** |  |  |  |  |
| Net income | $29052 | $32573 | $90873 | $47167 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization (inclusive of depreciation included in cost of service) | 6701 | 6358 | 13488 | 12496 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash compensation | 7905 | 8298 | 14749 | 16184 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization and impairment of operating lease right of use assets | 8750 | 8534 | 17395 | 17100 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on disposal of property and equipment | (11) | (23) | (45) | (19) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on equity method investment |  |  | (48093) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on termination of joint venture | (3568) |  | (3568) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 6414 | 3983 | 16395 | 6577 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity in earnings from equity method investments | (1641) | (1515) | (3435) | (2425) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of deferred debt issuance costs | 194 | 247 | 442 | 495 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Return on equity method investments | 1059 | 548 | 3379 | 718 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment | 883 |  | 883 |  |
| Changes in operating assets and liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patient accounts receivable | 24118 | 2449 | 554 | (44357) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 96 | 4823 | 3576 | 3127 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease right of use assets | (1178) | (1027) | (2364) | (2069) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | (40) | 215 | 48 | 370 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 1108 | (10345) | (9805) | (1693) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | (5008) | 4066 | (15666) | 7095 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term obligations |  | 18 | (34) | (573) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (7623) | (6897) | (15248) | (14429) |
| Net cash provided by operating activities | 67211 | 52305 | 63524 | 45764 |
| **Cash Flows from Investing Activities:** |  |  |  |  |
| Proceeds from the sale of deferred compensation plan assets |  |  | 27 | 21 |
| Proceeds from the sale of property and equipment | 4 |  | 19 |  |
| Purchases of property and equipment | (700) | (1385) | (1915) | (4055) |
| Investments in technology assets | (225) | (186) | (426) | (409) |
| Investment in equity method investee |  |  |  | (196) |
| Net cash used in investing activities | (921) | (1571) | (2295) | (4639) |
| **Cash Flows from Financing Activities:** |  |  |  |  |
| Proceeds from issuance of stock upon exercise of stock options | 56 |  | 149 |  |
| Shares withheld to pay taxes on non-cash compensation | (3141) | (3578) | (6005) | (4195) |
| Noncontrolling interest contributions |  | 147 |  | 1911 |
| Noncontrolling interest distributions | (475) | (1208) | (1260) | (1964) |
| Principal payments of long-term obligations | (9808) | (9441) | (19552) | (18382) |
| Debt issuance costs | (499) |  | (499) |  |
| Net cash used in financing activities | (13867) | (14080) | (27167) | (22630) |
| Net increase in cash, cash equivalents and restricted cash | 52423 | 36654 | 34062 | 18495 |
| Cash, cash equivalents and restricted cash at beginning of period | 284881 | 120704 | 303242 | 138863 |
| Cash, cash equivalents and restricted cash at end of period | $337304 | $157358 | $337304 | $157358 |
| **Supplemental Disclosures of Cash Flow Information:** |  |  |  |  |
| Cash paid for interest | $6182 | $7319 | $12359 | $15507 |
| Cash paid for income taxes, net of refunds received | $24423 | $17565 | $25330 | $18393 |
| Cash paid for operating lease liabilities | $8801 | $7924 | $17612 | $16498 |
| Cash paid for finance lease liabilities | $4181 | $4875 | $8302 | $7111 |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three-Month <br>Periods Ended June 30,** | **For the Three-Month <br>Periods Ended June 30,** | **For the Six-Month <br>Periods Ended June 30,** | **For the Six-Month <br>Periods Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Supplemental Disclosures of Non-Cash Activity:** |  |  |  |  |
| Right of use assets obtained in exchange for operating lease liabilities | $13375 | $3774 | $20381 | $10947 |
| Right of use assets obtained in exchange for finance lease liabilities | $3081 | $5691 | $6239 | $10017 |
| Reductions to right of use assets resulting from reductions to operating lease liabilities | $— | $— | $75 | $168 |
| Reductions to right of use assets resulting from reductions to finance lease liabilities | $273 | $623 | $688 | $1119 |
| Days revenue outstanding (1) | 40.9 | 52.1 | 40.9 | 52.1 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Our calculation of days revenue outstanding at June 30, 2025 and 2024 is derived by dividing our ending patient accounts receivable by our average daily patient revenue for the three-month periods ended June 30, 2025 and 2024, respectively.

------

**AMEDISYS, INC. AND SUBSIDIARIES**

**RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES**

**(Amounts in thousands, except per share data)**

***Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("Adjusted EBITDA") Reconciliation:***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three-Month <br>Periods Ended June 30,** | **For the Three-Month <br>Periods Ended June 30,** | **For the Six-Month <br>Periods Ended June 30,** | **For the Six-Month <br>Periods Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income attributable to Amedisys, Inc. | $28084 | $32301 | $89096 | $46701 |
| Add: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 19274 | 16657 | 48658 | 29290 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 3399 | 6278 | 6948 | 12670 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 6701 | 6358 | 13488 | 12496 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain items<sup>(1)</sup> | 23338 | 11566 | (8565) | 31862 |
| Adjusted EBITDA<sup>(2)(5)</sup> | $80796 | $73160 | $149625 | $133019 |

---

***Adjusted Net Income Attributable to Amedisys, Inc Reconciliation:***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three-Month <br>Periods Ended June 30,** | **For the Three-Month <br>Periods Ended June 30,** | **For the Six-Month <br>Periods Ended June 30,** | **For the Six-Month <br>Periods Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income attributable to Amedisys, Inc. | $28084 | $32301 | $89096 | $46701 |
| Add: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain items<sup>(1)</sup> | 23285 | 11240 | 3855 | 30788 |
| Adjusted net income attributable to Amedisys, Inc.<sup>(3)(5)</sup> | $51369 | $43541 | $92951 | $77489 |

---

***Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share Reconciliation:***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three-Month <br>Periods Ended June 30,** | **For the Three-Month <br>Periods Ended June 30,** | **For the Six-Month <br>Periods Ended June 30,** | **For the Six-Month <br>Periods Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income attributable to Amedisys, Inc. common stockholders per diluted share | $0.84 | $0.98 | $2.68 | $1.42 |
| Add: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain items<sup>(1)</sup> | 0.70 | 0.34 | 0.12 | 0.93 |
| Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share<sup>(4)(5)</sup> | $1.54 | $1.32 | $2.80 | $2.35 |

---

------

(1)&nbsp;&nbsp;&nbsp;&nbsp;The following details the certain items for the three and six-month periods ended June 30, 2025 and 2024:

***Certain Items (in thousands):***

---

| | | |
|:---|:---|:---|
| | **For the Three-Month <br>Period Ended June 30, 2025** | **For the Six-Month <br>Period Ended June 30, 2025** |
| | **(Income) Expense** | **(Income) Expense** |
| ***Certain Items Impacting General and Administrative Expenses:*** | | |
| Merger-related expenses | $26277 | $43046 |
| Impairment | 883 | 883 |
| ***Certain Items Impacting Total Other Income (Expense):*** |  |  |
| Other (income) expense, net (includes $48,093 gain on equity method investment during the six-month period ended June 30, 2025) | (3822) | (52494) |
| Total | $23338 | $(8565) |
| Net of tax | $23285 | $3855 |
| Diluted EPS | $0.70 | $0.12 |

---

---

| | | |
|:---|:---|:---|
| | **For the Three-Month <br>Period Ended June 30, 2024** | **For the Six-Month <br>Period Ended June 30, 2024** |
| | **(Income) Expense** | **(Income) Expense** |
| ***Certain Items Impacting General and Administrative Expenses:*** | | |
| Merger-related expenses | 11901 | 32568 |
| ***Certain Items Impacting Total Other Income (Expense):*** |  |  |
| Other (income) expense, net | (335) | (706) |
| Total | $11566 | $31862 |
| Net of tax | $11240 | $30788 |
| Diluted EPS | $0.34 | $0.93 |

---

(2) Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items as described in footnote 1.

(3)&nbsp;&nbsp;&nbsp;&nbsp;Adjusted net income attributable to Amedisys, Inc. is defined as net income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.

(4)&nbsp;&nbsp;&nbsp;&nbsp;Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.

(5)&nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measures calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.

## Exhibit 99.2

![](amed2q25ecsupplementalsl001.jpg)

1 Amedisys Second Quarter 2025 Earnings Release Supplemental Slides July 29, 2025 EXHIBIT 99.2

------

![](amed2q25ecsupplementalsl002.jpg)

2 This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those described in this presentation. You should not rely on forward-looking statements as a prediction of future events. Additional information regarding factors that could cause actual results to differ materially from those discussed in any forward-looking statements are described in reports and registration statements we file with the SEC, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, copies of which are available on the Amedisys internet website http://www.amedisys.com or by contacting the Amedisys Investor Relations department at (225) 292-2031. We disclaim any obligation to update any forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based except as required by law. www.amedisys.com NASDAQ: AMED We encourage everyone to visit the Investors Section of our website at www.amedisys.com, where we have posted additional important information such as press releases, profiles concerning our business, clinical operations and control processes and SEC filings. FORWARD-LOOKING STATEMENTS EXHIBIT 99.2

------

![](amed2q25ecsupplementalsl003.jpg)

3 HIGHLIGHTS AND SUMMARY FINANCIAL RESULTS (ADJUSTED): 2Q'25(1) 1. The financial results for the three-month periods ended June 30, 2024 and 2025 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Same Store volume – Includes admissions and recertifications. 3. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. 4. Free cash flow is defined as cash flow from operations less routine capital expenditures and required debt repayments. Growth Metrics: • Total Admissions: 1,073 (+29%) • Number of admitting JVs: 8 Other Statistics: • Patient Satisfaction: 90% High Acuity Care Adjusted Financial Results Same Store (3): • Admissions: +0.4% • ADC: +1.3% Other Statistics: • Revenue per Day: $179.96 (+4.1%) • Cost per day: $90.74 (+2.9%) HospiceHome Health Same Store(3) : • Admissions: +6% • Volume(2): +6% Other Statistics: • Medicare Revenue per Episode: $3,058 (+0.7%) • Cost per Visit: $119.82 (+2.3%) Amedisys Consolidated • Revenue: +5% • EBITDA: +10% • EBITDA Margin: 13.0% • Net Leverage ratio: 0.1x • Revolver availability: $508.0M • CFFO: $67.2M • DSO: 40.9 (vs. Q4'24 of 43.0 and down 11.2 days vs prior year) Amedisys Consolidated Amedisys Consolidated Regulatory 2025 Reimbursement • Final Hospice industry rule – industry estimated impact +2.9% increase (effective 10/1/24) • Final Home Health industry rule – industry estimated impact +0.5% increase (effective 1/1/25) 2026 Reimbursement • Proposed Hospice industry rule – industry estimated impact +2.4% increase (effective 10/1/25) • Proposed Home Health industry rule – industry estimated impact -6.4% decrease (effective 1/1/26) $ in Millions, except EPS 2Q24 2Q25 Home Health 377.4$396.2$ Hospice 204.0 215.0 High Acuity Care 9.8 10.7 Total Revenue 591.2$621.9$ Gross Margin % 45.0% 44.3% Adjusted EBITDA 73.2$80.8$12.4% 13.0% Adjusted EPS 1.32$1.54$ Free cash flow(4) 42.3$56.7$ EXHIBIT 99.2

------

![](amed2q25ecsupplementalsl004.jpg)

4 54.3% 17.6% 28.1% Home Health Revenue Medicare FFS Private Episodic & Case Rate Per Visit 63.7% 34.6% 1.7% Amedisys Consolidated Revenue Home Health Hospice High Acuity Care • Medicare FFS: Reimbursed for a 30-day period of care • Private Episodic: MA and Commercial plans who reimburse us for a 30-day period of care or 60-day episode of care, majority of which range from 90% - 100% of Medicare rates • Case Rate: Managed care payors who reimburse us per admission • Per Visit: Managed care, Medicaid and private payors who reimburse us per visit performed 95.4% 4.6% Hospice Revenue Medicare FFS Private Hospice Per Day Reimbursement: • Routine Care: Patient at home with symptoms controlled, ~97% of the Hospice care provided • Continuous Care: Patient at home with uncontrolled symptoms • Inpatient Care: Patient in facility with uncontrolled symptoms • Respite Care: Patient at facility with symptoms controlled • Home Health: 347 care centers; 34 states & D.C. • Hospice: 164 care centers; 31 states • High Acuity Care: 8 admitting joint ventures; 7 states; 32 referring hospitals • Total: 519 care centers/joint ventures; 38 states and D.C. OUR REVENUE SOURCES: 2Q'25 EXHIBIT 99.2

------

![](amed2q25ecsupplementalsl005.jpg)

5 HOME HEALTH AND HOSPICE SEGMENT (ADJUSTED) – 2Q'25(1) • Medicare revenue per episode up 0.7% primarily due to the 0.5% rate increase effective 1/1/2025. • Y/Y Total CPV up $2.68 (+2.3%) primarily due to raises, wage inflation, employee-related insurance costs and an increase in contract clinicians, salaried clinicians and clinical managers. • EBITDA margin decreased 80 basis points driven by wage increases and shift in admissions mix. Home Health Highlights • Net revenue per day +4.1% due to the +2.9% Hospice rate update effective 10/1/2024 and the mix in days. • Cost per day up $2.60 (+2.9%) primarily due to raises, wage inflation and investments in hospice clinical staffing. • EBITDA margin up 100 basis points primarily due to the 2025 rate increase (effective 10/1/2024) partially offset by raises. Hospice Highlights 1. The financial results for the three-month periods ended June 30, 2024 and 2025 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Pre-Corporate EBITDA does not include any corporate G&A expenses. 3. Same Store information represents the percent change in volume, admissions or ADC for the period as a percent of the volume, admissions or ADC of the prior period. 4. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. $ in Millions 2Q24 2Q25 Medicare 216.1$215.1$ Non-Medicare 161.3 181.1 Home Health Revenue $377.4 $396.2 Gross Margin % 43.1% 41.9% Pre-Corporate EBITDA(2) $70.7 $70.9 18.7% 17.9% Operating Statistics Same Store Growth(3)(4) Admissions 13% 6% Volume 9% 6% Medicare revenue per episode $3,036 $3,058 Medicare recert rate 31.8% 31.8% Total cost per visit $117.14 $119.82 HOME HEALTH $ in Millions 2Q24 2Q25 Medicare 193.7$205.1$ Non-Medicare 10.3 9.9 Hospice Revenue $204.0 $215.0 Gross Margin % 49.0% 49.6% Pre-Corporate EBITDA(2) $51.9 $56.8 25.4% 26.4% Operating Statistics Admit growth - same store(3)(4) -2.2% 0.4% ADC growth - same store(3)(4) 0.4% 1.3% ADC 12,968 13,132 Avg. discharge length of stay 90 93 Revenue per day (net) $172.88 $179.96 Cost per day $88.14 $90.74 HOSPICE EXHIBIT 99.2

------

![](amed2q25ecsupplementalsl006.jpg)

6 GENERAL & ADMINISTRATIVE EXPENSES – ADJUSTED (1,2) Notes: • Year over year total G&A as a percentage of revenue decreased 150 basis points • $0.6 million increase in total G&A is primarily due to planned wage increases and higher information technology costs partially offset by lower legal fees and a reduction in corporate support costs. • Total G&A remained flat sequentially as a seasonality driven increase in health insurance costs was offset by a reduction in corporate support costs. 1. The financial results for the three-month periods ended June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Adjusted G&A expenses do not include depreciation and amortization. Impacted by raises and information technology costs. 33.1% 33.7% 33.9% 33.0% 31.6% 31.0% 32.0% 33.0% 34.0% 35.0% 2Q24 3Q24 4Q24 1Q25 2Q25 Total G&A as a Percent of Revenue G&A as a Percent of Revenue $ in Millions 2Q24 3Q24 4Q24 1Q25 2Q25 Home Health Segment - Total 92.4$93.3$95.5$94.6$94.9$% of HH Revenue 24.5% 25.0% 25.3% 24.9% 24.0% Hospice Segment - Total 48.7 49.7 50.6 49.8 50.7 % of HSP Revenue 23.9% 23.9% 23.8% 24.2% 23.6% High Acuity Care Segment - Total 5.4 5.7 5.7 5.0 5.9 % of HAC Revenue 55.1% 74.2% 70.4% 53.2% 55.1% Total Corporate Expenses 49.2 49.6 50.8 46.7 44.8 % of Total Revenue 8.3% 8.4% 8.5% 7.9% 7.2% Total 195.7$198.3$202.7$196.1$196.3$% of Total Revenue 33.1% 33.7% 33.9% 33.0% 31.6% 2Q24 3Q24 4Q24 1Q25 2Q25 Salary and Benefits 27.4$29.9$30.3$27.5$25.9$ Other 17.4 15.6 16.3 15.4 14.8 Corp. G&A Subtotal 44.8 45.5 46.6 42.9 40.7 Non-cash comp 4.4 4.1 4.2 3.8 4.1 Adjusted Corporate G&A 49.2$49.6$50.8$46.7$44.8$ EXHIBIT 99.2

------

![](amed2q25ecsupplementalsl007.jpg)

7 INDUSTRY LEADING QUALITY SCORES Quality of Patient Care (QPC) Patient Satisfaction (PS) • Amedisys maintains a 4-Star average in the Jul 2025 HHC Final release with 89% of our providers (representing 89% of care centers) at 4+ Stars and 40% of our providers (representing 41% of care centers) at 4.5+ Stars. •11 Amedisys providers (representing 17 care centers) rated at 5 Stars. Notes: (1) Jul 2025 QPC Star Final performance period = Oct 2023 – Sep 2024. (2) Jul 2025 PS Final performance period = Jan 2024 – Dec 2024. (3) QPC Star and PS Results for Amedisys Legacy providers only. (4) Only currently active care centers included in care center results. Metric Oct 24 Final Jan 25 Final Apr 25 Final Jul 25 Final Quality of Patient Care 4.24 4.18 4.15 4.16 Entities at 4+ Stars 89% 88% 88% 89% Metric Oct 24 Final Jan 25 Final Apr 25 Final Jul 25 Final Patient Satisfaction Star 3.78 4.02 3.76 3.69 Performance Over Industry +3% +4% +2% +1% 3.00 3.50 4.00 4.50 Oct 2022 Jan 2023 Apr 2023 Jul 2023 Oct 2023 Jan 2024 Apr 2024 Jul 2024 Oct 2024 Jan 2025 Apr 2025 Jul 2025 QPC Industry Performance Amedisys QPC Industry Avg QPC Top Competitor 3.00 3.50 4.00 4.50 Oct 2022 Jan 2023 Apr 2023 Jul 2023 Oct 2023 Jan 2024 Apr 2024 Jul 2024 Oct 2024 Jan 2025 Apr 2025 Jul 2025 PS Industry Performance Amedisys PS Industry Avg PS Top Competitor EXHIBIT 99.2

------

![](amed2q25ecsupplementalsl008.jpg)

8 HOSPICE QUALITY: AMEDISYS HOSPICE CONTINUES TO MOVE TOWARDS BEST-IN-CLASS Hospice Quality Notes: Included in the above analysis are only active providers. National is an average of all providers nationally, excluding active AMED providers. EXHIBIT 99.2

------

![](amed2q25ecsupplementalsl009.jpg)

9 DEBT AND LIQUIDITY METRICS Net leverage ~0.1x 1. Net debt defined as total debt outstanding ($364.8M) less cash and cash equivalents ($337.3M). 2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($262.4M). 3. Liquidity defined as the sum of cash balance and available revolving line of credit. Outstanding Term Loan 338.1$ Outstanding Revolver - Finance Leases 26.7 Total Debt Outstanding 364.8 Less: Deferred Debt Issuance Costs (1.6) Total Debt - Balance Sheet 363.2 Total Debt Outstanding 364.8 Less Cash & Cash Equivalents (337.3) Net Debt (1) 27.5$ Leverage Ratio (net) (2) 0.1 Term Loan 450.0$ Revolver Size 550.0 Borrowing Capacity 1,000.0 Revolver Size 550.0 Outstanding Revolver - Letters of Credit (42.0) Available Revolver 508.0 Plus Cash & Cash Equivalents 337.3 Total Liquidity (3) 845.3$ As of: 6/30/25 Credit Facility Outstanding Debt As of: 6/30/25 EXHIBIT 99.2

------

![](amed2q25ecsupplementalsl010.jpg)

10 CASH FLOW STATEMENT HIGHLIGHTS (1) 2Q'25 operating cash of $67M reflects strong accounts receivable collections. 1. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments. $ in Millions 2Q24 3Q24 4Q24 1Q25 2Q25 GAAP net income (loss) 32.6$1 6.5$(25.5)$61 .8$29.1$ Changes in working capital 1 .0 7 5.2 34.0 (41 .7) 20.3 Depreciation and amortization 6.4 6.8 6.7 6.8 6.7 Non-cash compensation 8.3 6.2 8.2 6.8 7 .9 Deferred income taxes 4.0 0.8 - 1 0.0 6.4 Impairment - - 48.4 - 0.9 Other - 0.1 (1 .5) (47 .4) (4.1) Cash flow from operations 52.3 105.6 70.3 (3.7) 67.2 Capital expenditures - routine (0.6) (1 .1) (0.9) (1 .2) (0.7) Required debt repay ments (9.4) (9.3) (9.6) (9.7) (9.8) Free cash flow 42.3$95.2$59.8$(14.6)$56.7$ EXHIBIT 99.2

------

![](amed2q25ecsupplementalsl011.jpg)

11 INCOME STATEMENT ADJUSTMENTS (1) 1. The financial results for the three-month periods ended June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025 have been adjusted for the certain items above. A reconciliation of our non-GAAP financial measures, which include these certain items, is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Other (income) expense, net includes a $48.1 million gain on an equity method investment recorded during the three-month period ended March 31, 2025. 2Q'25 adjustments primarily related to costs associated with pending merger and joint venture/investment impairments. $000s Income Statement Line Item 2Q24 3Q24 4Q24 1Q25 2Q25 G&A Merger-related expenses General and Administrativ e Expenses 1 1 ,901$1 6,669$1 7 ,401$1 6,7 69$26,27 7$ Impairment General and Administrativ e Expenses - - 48,391 - 883 Other Items Other (income) expense, net (2) Other Income (Expense) (335) (538) (2,1 23) (48,67 2) (3 ,822) Impairment Net Loss Attributable to Noncontrolling Interests - - (5,867) - - Total 11,566$16,131$57,802$(31,903)$23,338$ EPS Impact 0.34$0.49$1.58$(0.59)$0.70$ EBITDA Impact 11,566$16,131$57,802$(31,903)$23,338$ EXHIBIT 99.2

------